68 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
The Company has long-term arrangements with commitments that are not recognized as liabilities as at March 31, 2024 and December 31, 2023 … are as follows:
Employment Agreements
March 31,
December 31,
Management services – officers
The President, CEO, and a director of the Company has a long-term employment
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
to 32,000 patients on long-term renal therapy were attributable to ADPKD, making it the fourth leading cause of new kidney disease cases behind diabetes … from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. The results of Phase 4 clinical
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
and 2022
(Unaudited - expressed in U.S. Dollars)
Commitments
The Company has long-term arrangements with commitments that are not recognized … which as of December 31, 2022, equated to an annual salary of CAD $192,000.
The President, CEO and a director of the Company has a long-term employment
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
The Company has long-term arrangements with commitments that are not recognized as liabilities as at March 31, 2024 and December 31, 2023 … . As the operations comprise a single reporting segment, amounts disclosed also represent segment amounts. All long-term assets of the Company are located
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
to 32,000 patients on long-term renal therapy were attributable to ADPKD, making it the fourth leading cause of new kidney disease cases behind diabetes … from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. The results of Phase 4 clinical
424B3
zycnkr
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.1
b1abws6
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.2
a94g83ba12evk4
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
424B5
gg12f6pem6atcuto
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
drd0zr4
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.1
wnkmk nc7
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.1
2sasbcvk2c9 t4s9ejkk
12 Oct 23
XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
7:41am
424B3
fxk cpq9v
25 Aug 23
Prospectus supplement
6:00am
424B3
hfm46
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
fddczk1mpq5r7j
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
6-K
EX-99.1
rp7h14vhhr8m2y0ar2
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
o9rfrkk5pun
14 Aug 23
Prospectus supplement
4:42pm
424B3
qxxqh7tpd sj
14 Aug 23
Prospectus supplement
4:40pm